Symphogen A/S has closed a €67.5 million (US$75.4 million) convertible debt facility from existing investors that will help the company advance its pipeline, led by Sym004, an antibody mixture currently in a phase IIb study for metastatic colorectal cancer (mCRC) patients with disease resistance or who are refractory to antibody therapies targeting epidermal growth factor receptor.